SLF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. SLF’s longer-term trend looks constructive (bullish moving-average stack), but near-term momentum is deteriorating (MACD histogram negative and expanding) and price is sitting just below the pivot (~63.11) with immediate resistance overhead. With earnings (Q4/FY25) coming on 2026-02-11 after hours and recent quarter profitability down YoY, the risk/reward for an impatient entry today is not favorable. I would hold (or stay on the sidelines) rather than buy immediately.
Price/levels: SLF at 62.85 (-1.49%) is below the pivot 63.11, with near support at S1 62.405 then S2 61.97; resistance is R1 63.815 and R2 64.25. Momentum: MACD histogram -0.0426 is below zero and worsening, signaling weakening short-term momentum. RSI(6) 47.78 is neutral (no oversold bounce signal). Trend: moving averages are bullish (SMA_5 > SMA_20 > SMA_200), implying the broader uptrend is intact, but the near-term pullback is still in progress. Pattern-based forward bias provided: ~50% chance of -0.81% next day, -0.97% next week, +4.35% next month—near term slightly negative, medium-term modestly positive.
Intellectia Proprietary Trading Signals
Upcoming event catalyst: Q4 and full-year 2025 results on 2026-02-11 (after hours) and analyst call on 2026-02-12 could re-rate the stock if results/guide are better than feared. Broader trend support: bullish moving-average structure suggests the longer-term trend can still support upside if momentum stabilizes. Options positioning: OI put/call of 0.52 leans constructive (more call open interest than puts).
Near-term technical deterioration: negative and worsening MACD suggests momentum is currently against immediate buying. Event risk: earnings in ~2 weeks can create downside gap risk if profit metrics or segment experience (e.g., U.S. Dental/stop-loss) disappoint. Fundamental pressure: latest reported quarter shows declining profitability (net income and EPS down YoY), which can weigh on sentiment into earnings. No notable supportive flow signals: hedge funds and insiders reported as neutral; no notable congress trading data.
Latest quarter provided: 2025/Q3. Revenue increased to 8.986B (+3.00% YoY), but profitability weakened: net income 1.106B (-17.95% YoY) and EPS 1.97 (-15.45% YoY). This indicates modest top-line growth but margin/earnings pressure—important context heading into Q4/FY25 earnings (2026-02-11).
Recent Street trend is neutral-to-cautious. Barclays (2026-01-08) kept Underweight and slightly cut PT to C$83 (bearish outlier). CIBC (2026-01-08) is Neutral with PT raised to C$95. Morgan Stanley (2025-12-15) stayed Equal Weight with PT raised to C$91. RBC (2025-11-07) downgraded to Sector Perform (PT C$84) citing U.S. segment experience losses (Dental/stop-loss) and ongoing Dental challenges. Scotiabank and National Bank remain Sector Perform with mid/high-80s to low-90s CAD targets. Wall Street pros: capital strength/cash flow and stable macro backdrop are supportive; cons: spread compression/tech spend headwinds and segment-specific experience losses keep upside capped. Overall consensus positioning reads as “hold/market perform,” not an aggressive buy.
